Modality
Bispecific Ab
MOA
DLL3 ADC
Target
IL-23
Pathway
RNA Splicing
MG
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
Phase 2Current
NCT04120822
1,228 pts·MG
2018-02→TBD·Recruiting
1,228 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04120822 | Phase 2/3 | MG | Recruiting | 1228 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 | |
| Talafotisoran | Blueprint Medicines | Phase 2/3 | IL-23 |